Stay updated on Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.

Latest updates to the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page
- Check2 days agoChange DetectedRevision label on the page updated to v3.6.5, replacing the previous v3.6.4. This signals a minor update to the study record metadata rather than changes to study details.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4 in the page footer, indicating a small site update with no changes to study details or navigation.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedThe page now shows revision: v3.6.3, replacing the previous v3.6.2. This indicates a minor metadata/format update to the page rather than a substantive change to content.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a refreshed or corrected version of the study record.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page now lists the investigator and sponsor names as additions and adds several navigation/help items (How to Read a Study Record, Common Questions, How to Join a Study) along with an updated label (Intervention/Treatment) and a new revision tag (Revision: v3.6.0). It also removes older labels and references (Last known status was, Verified) and the prior version tag (Revision: v3.5.5).SummaryDifference1%

- Check67 days agoChange DetectedThe page revision changed from v3.5.4 to v3.5.5, indicating a new version of the page. This is a metadata update rather than a substantive change to the study information.SummaryDifference0.1%

Stay in the know with updates to Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.